Impact Network - Healthcare Research’s Post

Participation in breast cancer research is not only a meaningful way for patients to support their community but also a crucial step in advancing our understanding of the disease and improving patient outcomes. By engaging in research studies and clinical trials, patients like Diane become an integral part of the broader effort to fight breast cancer. Click the link below to learn more about how our early breast cancer dataset is informing novel treatments with the true patient experience. https://lnkd.in/efMqPG2U #BreastCancerAwareness #PatientCentricity #RealWorldData #RealWorldEvidence

#Breastcancer is a topic that has garnered significant attention over the years, and for good reason. Affecting millions worldwide, it remains one of the most common forms of #cancer among women. While early detection and advancements in treatment have improved prognosis for many, metastatic breast cancer (MBC) remains a significant challenge in the #oncology world. By definition, #metastatic breast cancer is when cancer has spread beyond the breast and axillary lymph nodes to other parts of the body. Recently we published an in-depth article giving details on this subject including an interview with Virginia Kaklamani, MD during #ASCO23 Check out now: https://buff.ly/3KxYv9p Learn about expert insights, and personalized approaches for improved outcomes. #UTHeathSanAntonio

Pancreatic cancer continues to have one of the highest mortality rates of all major cancers, with over 64,000 Americans diagnosed in 2023 alone. In our latest CAPcast, explore what’s on the horizon for pancreatic cancer research, how it will impact patient outcomes, and the role of pathology data in these efforts. Listen Today. https://brnw.ch/21wESt7

Early detection and treatment are imperative for improving breast cancer survival rates. The emergence of radiogenomics within precision medicine is a promising avenue. This article by a team of authors, including Fortrea’s Kamal Saini, MD, Executive Medical Director, delves into the theoretical underpinnings and explores practical applications in the diagnosis, management and treatment of breast cancer. https://lnkd.in/eBbYbtbK

CHA Project Highlight: Improving Cancer Screening in Underserved High-Risk Populations - Lisa Barker, MD, FACEP, OSF HealthCare - Elizabeth Papautsky, PhD, MS, University of Illinois Chicago This project seeks to characterize the current barriers to completion of screening recommendations among patients at high risk for breast cancer, then use that data to create and pilot test an “intervention bundle” to optimize rates of breast MRI completion for eligible high-risk patients. With attention to the underserved communities within the OSF service population, this project will contribute to reduced health disparities by reducing barriers to care in the context of timely breast cancer diagnosis. https://lnkd.in/gJge-QMe

Gilead Sciences has recently published a manuscript in Breast Cancer Research and Treatment, shedding light on the real-world use patterns, effectiveness, and tolerability of Sacituzumab govitecan (SG) for patients with metastatic triple-negative breast cancer (mTNBC) in the United States. This study included 230 diverse patients using ConcertAI's Patient360™ + custom curation database. SG, along with G-CSF, was common in treatment. These findings support SG as a second-line treatment for mTNBC and the data from this study reinforce the positive outcomes seen in clinical trials, providing hope for patients facing this challenging diagnosis. Read manuscript: https://hubs.ly/Q02DW-NL0 #BreastCancerResearch #SGTreatment #MetastaticTNBC #GileadResearch #Patient360

Recent advances in molecular diagnostics have led to a significant shift in the management of early-stage, hormone receptor-positive, HER2-negative breast cancer. Increasingly, the need for chemotherapy is being re-evaluated as we gain more insights from clinical trials and genetic testing. The routine practice of omitting chemotherapy, which spares patients from its potential adverse effects without compromising the efficacy of the treatment, is gaining ground. Through my podcast, I delve into the role of the Oncotype DX assay along with other multi-gene tests such as Mammaprint and Prosigna in determining which patients are likely to benefit from chemotherapy and which can avoid it. The findings from pivotal studies like the TAILORx and RxPonder trials are exemplary of how personalized medicine is revolutionizing the treatment landscape in breast oncology. For more information, please follow me at https://lnkd.in/e2PXW8RK. Disclaimer: The information presented in this video is for educational purposes only. It should not be considered medical advice. #cancer #breastcancer #chemotherapy

Pancreatic cancer continues to have one of the highest mortality rates of all major cancers, with over 64,000 Americans diagnosed in 2023 alone. In our latest CAPcast, explore what’s on the horizon for pancreatic cancer research, how it will impact patient outcomes, and the role of pathology data in these efforts. Listen Today. https://brnw.ch/21wES6m

Pancreatic cancer is often difficult to diagnose. If the cancer is detected at an early stage (only 12%) when surgical removal of the tumor is possible, the 5-year relative survival rate is 44%. For the 52% of people who are diagnosed after the cancer has spread to a distant part of the body, the 5-year relative survival rate is 3%.

Dr. Burstein, Medical Oncologist at Dana-Farber Cancer Institute is an internationally renowned breast cancer expert. He and medical advancements are responsible for saving the life of one of our DetecTogether employees. “Dr. Burstein is brilliant and kind. He gave me hope and reassurance when I needed it most. Breast cancer is often curable when caught early." Watch as he talks about some barriers to timely care and the importance of activating your own healthcare - what 3 Steps Detect is all about: https://bit.ly/408R4vX #breastcancerscreening #breastcancerawareness #breastcancerawarenessmonth #3stepsdetect #earlycancerdetection #danafarber